Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-04-23 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于公司2023年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2023 annual profit distribution plan, including details on dividends and capital reserve transfers. It references board and supervisory meetings approving the plan and states that the plan will be submitted to the 2023 annual shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The document length is 2047 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV) announcement rather than an Annual Report or Interim Report.
2024-04-23 Chinese
2023年内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制评价报告" (Internal Control Evaluation Report) for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. as of December 31, 2023. It details the company's internal control evaluation, covering governance, organizational structure, financial management, risk assessment, and internal control effectiveness. The document is comprehensive, over 11,000 characters, and contains detailed descriptions of internal control systems, evaluation standards, and conclusions about the effectiveness of internal controls. It is not an annual report, audit report, or earnings release, but a specialized report focused on internal control evaluation as required by regulatory standards. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-23 Chinese
2023年度独立董事述职报告 （尤启冬）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2023 by an independent director of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the director's attendance at board meetings, opinions on various company matters, participation in committees, communication with auditors, and overall evaluation of their duties. The content focuses on governance, oversight, and the director's role in protecting shareholder interests, rather than financial results or audit opinions alone. It is not a full annual report, audit report, or earnings release. It is a detailed report on board/management activities and director duties, consistent with Board/Management Information filings. The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-04-23 Chinese
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2023 (January 1, 2023 to December 31, 2023). It contains detailed audit opinions, key audit matters, management responsibilities, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of a formal audit opinion by a registered accounting firm and detailed financial data confirms this is a standalone audit report with accompanying financial statements, not a full annual report or just an announcement. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2023
2024-04-23 Chinese
关于2023年度募集资金存放和使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. for the fiscal year 2023. It includes specifics on the amount raised, the timing of fund receipt, usage details, balances, regulatory compliance references, and approvals by the board. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it includes financial figures and tables related to the raised funds. The content focuses on the management and usage of raised capital, including investment projects, cash management, and surplus funds. This matches the characteristics of a specialized report on fundraising capital usage rather than a general annual report or earnings release. The document is not a brief announcement or a certification letter but a substantive report with financial data and regulatory compliance details. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-23 Chinese
董事会对独董独立性评估的专项意见
Regulatory Filings Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines related to independent directors and confirms compliance with independence requirements. There is no financial data, no mention of financial results, no voting results, no capital changes, no legal proceedings, or other report types. The document is a regulatory compliance statement related to governance but does not fit the detailed governance report category (CGR) as it is a specific opinion on director independence. It is a regulatory announcement related to board matters but not a management change announcement (MANG). Given the nature and length, it best fits under Regulatory Filings (RNS) as a compliance disclosure that does not fit other categories.
2024-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.